

# ICH CGT DG

Cell and Gene Therapy Discussion Group

**December 18, 2024**

**Atsushi Nishikawa, PMDA, TL**  
**Satoshi Yasuda, NIHS, DTL**

**Yuki Miyatake, JPMA, TL**  
**Hiroaki Miida, JPMA, DTL**  
**Yoko Watanabe, JPMA**  
**Masato Komuro, JPMA**

# Outline

- ▶ Overview of topic
- ▶ Status before the meeting
- ▶ Progress made at the meeting
- ▶ Status at the end of the meeting
- ▶ Work Plan: Key Milestones and Activities
- ▶ Conclusions

# Overview: Scope

- **Initial focus on more mature product classes**
  - *Ex vivo* genetically modified cells (e.g. chimeric antigen receptor T-cell products (e.g., CAR T-cells)) including both autologous and allogeneic
  - *In vivo* viral vector-based gene therapies (e.g., AAV vector-based gene therapy products)
- **Challenges:**
  - There are often challenges in scope of product classes given rapid evolution in genetic modification technologies
  - Advanced Therapy Medicinal Product (ATMP) terminology
  - Disciplines: Clinical, Nonclinical, and Quality
    - Intent to address interdependencies
  - Other EWGs are asked to address *all ATMP* product classes

# ICH CGT DG Members

## **Regulatory/Administrative Authorities**

- EU commission, Europe
- FDA, USA
- MHLW/PMDA, Japan
- ANVISA, Brazil
- EDA, Egypt
- HSA, Singapore
- MFDS, Republic of Korea
- MHRA, UK
- NMPA, China
- SFDA, Saudi Arabia
- TFDA, Chinese Taipei
- Health Canada, Canada
- Swissmedic, Switzerland
- ANMAT, Argentina
- ANPP, Algeria

## **Industry Associations**

- EFPIA
- JPMA
- PhRMA
- BIO
- IFPMA
- IGBA

## **Other/International Associations**


- EDQM
- USP
- IPRP
- WHO

# Status before the ICH meeting


## Deliverables:

1. High level principles document – **draft done** (current working draft with additional updates planned)
2. Overview of global regulatory framework – **draft done**
3. Areas of divergence and harmonization in regulatory expectations – **draft done**
4. Stepwise review of existing ICH guidelines for applicability to ATMPs – **in progress**
5. Holistic ATMP strategic roadmap – **in progress**
6. Recommendation paper – final deliverable due Oct 2025

# Work Plan Milestones Timeline



# ATMP Global Regulatory Framework



- ❖ Nearly 400 ATMP-specific guidelines and regulations across regulatory agencies participating in CGT DG (Feb 2024).

# Areas of divergence in regulatory expectations

- Divergence that developers encountered while trying to conduct global clinical trials and/or commercialize ATMPs in multiple regions globally.
- Surveys conducted to gather info (Feb 2024); Compiled information gathered by trade groups (Feb - May 2024). Ranked according to priority (high-medium-low)
- Key challenges identified by regulators – ranked according to priority (high-medium-low)
- Issues/topics identified and prioritized by regulators and industry/trade associations – largely aligned perspectives from trades and regulators



# Mapping priority issues/topics to existing ICH guidelines

## Table of Contents

### Efficacy Guidelines

E1.....	5
E2A.....	10
E2B(R3) Q&A.....	22
E2C(R2).....	52
E2C(R2) Q&A.....	93
E2D.....	115
E2D(R1) DRAFT.....	130
E2E.....	160
E2F.....	180
E3.....	215
E3 Q&As.....	265
E4.....	275
E5(R1).....	299
E5(R1) Q&A.....	289
E6 (R2) Addendum.....	316
E6 (R3) DRAFT.....	382
E7.....	461
E7 Q&A.....	467
E8(R1).....	474
E9.....	503
E9(R1).....	542
E10.....	564
E11(R1) Addendum.....	599
E11A.....	624
E12A Consensus Principles.....	657
E14.....	667
E14 (R3) Q&A.....	685
E15.....	703
E16.....	713

### Multidisciplinary Guidelines

E17.....	726
E18.....	755
E19.....	766
M3(R2).....	809
M3(R2) Q&A.....	781
M7(R2).....	981
M7(R2) Addendum.....	840
M7(R2) Q&A.....	1013
M9.....	1032
M9 Q&A.....	1053
M10.....	1066
M10 Q&A.....	1123
M11 DRAFT.....	1128
M12.....	1135
M12 Q&A.....	1209
M13A.....	1218
M13A Q&A.....	1243
M14 DRAFT.....	1259

## Table of Contents

### Quality Guidelines

Q1A(R2).....	1308
Q1B.....	1332
Q1C.....	1344
Q1D.....	1347
Q1E.....	1358
Q1F.....	1378
Q1F Withdrawal Explanatory Note.....	1377
Q2(R2).....	1422
Q3A(R2).....	1458
Q3B(R2).....	1473
Q3C(R9).....	1489
Q3D(R2).....	1539
Q4B.....	1681
Q4B(R1).....	1745
Q4B FAQ.....	1692
Q4B ANNEX 1(R1).....	1698
Q4B ANNEX 2(R1).....	1704
Q4B ANNEX 3(R1).....	1710
Q4B ANNEX 4A(R1).....	1719
Q4B ANNEX 4B(R1).....	1725
Q4B ANNEX 4C(R1).....	1733
Q4B ANNEX 5(R1).....	1739
Q4B ANNEX 6.....	1627
Q4B ANNEX 7(R2).....	1633
Q4B ANNEX 8(R1).....	1640
Q4B ANNEX 9(R1).....	1646
Q4B ANNEX 10(R1).....	1652
Q4B ANNEX 11.....	1658
Q4B ANNEX 12.....	1664
Q4B ANNEX 13.....	1670
Q4B ANNEX 14.....	1676
Q5A(R2).....	1752
Q5B.....	1814
Q5C.....	1810
Q5D.....	1820
Q5E.....	1837
Q6A.....	1864
Q6A Decision Trees.....	1888
Q6B.....	1899
Q7.....	1919
Q7 Q&A.....	1968
Q8(R2).....	2027
Q9(R1).....	2055
Q10.....	2084
Q8/Q9/Q10 - Points to Consider.....	1989
Q8/Q9/Q10 Q&A.....	2010
Q11.....	2105
Q11 Q&A.....	2135
Q12.....	2184
Q12 Annexes.....	2154
Q13.....	2215
Q14.....	2261

## Table of Contents

### Safety Guidelines

S1A.....	2301
S1B (R1).....	2309
S1C (R2).....	2334
S2 (R1).....	2346
S3A.....	2375
S3A Q&A.....	2390
S3B.....	2399
S4.....	2403
S5 (R3).....	2407
S6(R1).....	2527
S7A.....	2550
S7B.....	2563
E14/S7B Q&As.....	2578
S8.....	2623
S9.....	2638
S9 Q&A.....	2651
S10.....	2670
S11.....	2689
S12.....	2732

### ICH Consideration Documents

General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors.....	2743
Oncolytic Viruses.....	2746
General Principles to Address Virus and Vector Shedding.....	2751
Sex-Related Considerations in the conduct of Clinical Trials.....	2757



- A large PDF consolidation activity created keyword-searchable files, aiding in the topic mapping process. Includes: All Guidelines, Q&As, consideration documents, and drafts available as of September 2024. **(2,765 total pages)**
- Assess applicability of ICH guidelines to ATMPs

# Topic Mapping Template

1. Please review the preliminary <b>keyword results</b> above to ensure better accuracy. Update the table (delete/add guidelines as needed). Add any additional keywords used (synonyms, related concepts etc.) Explain the revisions here: -
2. Which ICH Guideline(s) <b>primarily define ICH's current position on this topic</b> , including considerations for both ATMPs (if specified) and general (i.e. traditional) drug development? -
3. Please copy/paste the <b>relevant text</b> (or refer to the Guideline's sections/entirety if too long to copy/paste) demonstrating ICH's thinking on this topic, including considerations for both ATMPs (if specified) and general (i.e. traditional) drug development: -
4. Consider the identified text for its <b>applicability</b> to the identified topic in the context of <i>in-vivo</i> viral-vector based gene therapies (e.g., AAVs) and <i>ex vivo</i> genetically modified cells (e.g., CAR-Ts). Does the current text apply, partially apply, or not apply, and why? Highlight potential challenges or gaps. -
5. Please provide your <b>recommendation(s) about how ICH could address this topic</b> as it relates to the two modalities (e.g., New Guideline, Revised Guideline, Annex, no action needed, etc.) -
6. Please list the primary <b>national or regional guidance(s)</b> that addresses this topic specifically for ATMPs: -

❖ This activity is ongoing and conducted uniformly across subgroups.

# Advise other EWG

- ▶ "The CGTDG is not tasked with the development or revisions of specific ICH Guidelines but may act as an advisor group to existing ICH Expert Working Group (EWG) undergoing new or revised guideline development where CGT products are in scope."
  - ✓ Completed: Review ATMP Annex for ICH Q1/Q5c Stability Revision EWG (January, 2024).
  - ✓ Advise: ICH Q6 Specifications Revision EWG

# Progress made at the meeting

- ▶ Met with Q6 Specification EWG and with Q1 Stability EWG – shared relevant sections HLP document; global map of ATMP regulations; searchable PDFs of all ICH guidelines; prioritized issues/topics
- ▶ Mapping issues/topics to ICH guidelines as subgroups and DG: Quality, Non-clinical and Clinical
- ▶ For ICH Topic Proposal, narrowed from 20+ topics to 5 suggestions to top 2:
  - ✓ Multidisciplinary guideline on unique ATMP development considerations w/ first annex on Comparability
  - ✓ Comparability (Annex to ICH Q5E)

# Topic Proposal by 22 Nov 2024

- ICH Multidisciplinary (M) guideline on Unique ATMP Development Considerations with first annex on Comparability
- Proposing members:
  - **BIO (lead)**
- Vote among CGT DG members supported topic proposal by majority

# Work Plan:

## Expected Future Key Milestones

Expected Completion date	Deliverable
Apr 2025	("Interim Deliverable 4") Review existing ICH guidelines (Q, S, E, M) in terms of their applicability to CGT product classes in scope and identify areas where harmonisation already exists and areas for improvement in harmonisation
Jun 2025	("Deliverable 5") Holistic CGT roadmap w/ prioritization of areas in most need of harmonization with recommendations for revisions to existing ICH guidelines and/or possibly new guideline development
Oct 2025	("Deliverable 6") Recommendation paper summarizing high level principles and roadmap described above, for ICH MC and Assembly review and endorsement

# Conclusions

- ▶ CGT DG has completed several interim deliverables and is on track to fulfill remit on ATMP modalities in the initial focus by October 2025

The background features abstract, overlapping geometric shapes in various shades of blue, ranging from light sky blue to deep navy blue. These shapes are primarily located on the left and right sides of the frame, creating a modern, dynamic border around the central text.

**Thank you!**